Showing 231-240 of 328 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Understanding common tissue tolerance mechanisms in autoimmunity | Massachusetts General Hospital | Gary Reynolds | Cures | 01-September-2025 to 31-August-2026 | $150,000.00 |
| Development of a safe and effective islet-targeted nanoplasmid based CXCL12 gene delivery system using cationic nanobubble-mediated sonotransfection to restore and immune protect the residual beta cell mass in T1D | Massachusetts General Hospital | Mark Poznansky | Cures | 01-April-2023 to 31-March-2026 | $777,168.00 |
| Demand for Combined CGM-Pump Devices in Type 1 Diabetes | Magnolia Innovation, LLC | Kenneth Howie | Improving Lives | 01-August-2025 to 15-February-2026 | $291,000.00 |
| T1D Adjunct Therapy Product & Patient Profiling Study | Magnolia Innovation, LLC | Kenneth Howie | Improving Lives | 01-December-2024 to 30-September-2025 | $434,000.00 |
| Transcriptional memory in human islet organogenesis | Lundquist Institute for Biomedical Medical Innovation at Harbor‐UCLA Medical Center (The Lundquist Institute) | Eiji Yoshihara | Cures | 01-April-2022 to 31-March-2027 | $749,995.50 |
| Innovation Partnership | LabCentral | Luke Wallrich | Cures | 07-July-2025 to 31-May-2026 | $200,000.00 |
| Program to Achieve FDA Agreement on Design of Confirmatory Trial for Verapamil | Kinexum LLC | Michael Zemel | Cures | 01-December-2024 to 30-June-2025 | $160,000.00 |
| Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease: The SUGARNSALT Trial | Joslin Diabetes Center Inc. | Alessandro Doria | Improving Lives | 01-January-2024 to 31-December-2028 | $8,913,450.00 |
| Study of ALDH3B2 as a regulator of pancreatic beta cell neogenesis | Joslin Diabetes Center Inc. | Jian Li | Cures | 01-August-2023 to 31-July-2026 | $212,708.89 |
| Validation of a new approach for cardiovascular disease risk stratification and therapeutic targeting in T1D | Joslin Diabetes Center Inc. | Myra Lipes | Improving Lives | 01-September-2023 to 31-December-2025 | $966,378.00 |